Maxim Group reaffirmed their hold rating on shares of Biostage, Inc. (NASDAQ:BSTG) in a research note published on Monday.

Shares of Biostage (BSTG) opened at 0.56 on Monday. Biostage has a 1-year low of $0.22 and a 1-year high of $1.42. The firm’s 50-day moving average is $0.46 and its 200 day moving average is $0.40. The stock’s market capitalization is $20.78 million.

Biostage (NASDAQ:BSTG) last posted its quarterly earnings results on Thursday, May 11th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.09. On average, analysts expect that Biostage will post ($0.36) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Biostage’s (NASDAQ:BSTG) “Hold” Rating Reiterated at Maxim Group” was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international trademark & copyright law. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2017/08/10/biostages-nasdaqbstg-hold-rating-reiterated-at-maxim-group.html.

About Biostage

Biostage, Inc, formerly Harvard Apparatus Regenerative Technology, Inc, is a biotechnology company. The Company is engaged in developing bioengineered organ implants based on its Cellframe technology. Its Cellframe technology consists of a biocompatible scaffold that is seeded with the recipient’s own cells.

Receive News & Stock Ratings for Biostage Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biostage Inc. and related stocks with our FREE daily email newsletter.